Clinical trials: Hep A
HIV Infection, Hepatitis C Infection
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV).
- Trial name
- NCT00991289
- Testing
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis b
Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers
A single-center, open-Label, randomized, single-dose, two-period, two-sequence, crossover study to assess the bioequivalence of test formulation entecavir tablets 1.0 mg with reference formulation entecavir tablets (Baraclude®)…
- Trial name
- NCT03847246
- Testing
- Baraclude® tablets,1.0 mg, Entecavir tablets,1.0 mg
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HEPATITIS C (HCV)
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
The metabolism of PF-00868554 is primarily mediated by CYP3A, and it is anticipated that hepatic impairment will modify PF-00868554 plasma concentrations.
- Trial name
- NCT00651027
- Testing
- PF-868554
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
HEPATITIS C (HCV)
Lay User Evaluation of the Panbio™ HCV Self-Test
This is a prospective, multi-centre study designed to evaluate the usability of the Panbio™ HCV Self Test, when performed by untrained lay users in an observed study setting.
- Trial name
- NCT06605573
- Testing
- Panbio™ HCV Self Test
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
Hepatitis B, Chronic
Study of AHB-171 in Chronic Hepatitis B Participants
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB).
- Trial name
- EXTEND-101 (NCT07617194)
- Testing
- AHB-171, Nucleos(t)ide Analogue (NA)
- Where
- 2 sites in Hong Kong, New Zealand
- Volunteers
- 144 people
- Sponsor
- AusperBio Therapeutics Inc.
Chronic Hepatitis C
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration.
- Trial name
- NCT00487318
- Testing
- standard of care, fluvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis B Reactivation
TAF to Prevent HBV Reactivation in Cancer Patients
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing.
- Trial name
- NCT04619082
- Testing
- Tenofovir alafenamide
- Where
- 5 sites in Taiwan
- Volunteers
- 102 people
- Sponsor
- Chiayi Christian Hospital
Hepatitis C, Chronic
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
The purpose of this study is to explore whether silibinin plus ribavirin with/without peg-interferon can be more effective than the peg-interferon plus ribavirin based standard of care (SoC) in the treatment of patients infected…
- Trial name
- HEPASIL (NCT01871662)
- Testing
- Legalon® SIL (Silibinin), Pegylated interferon alfa2b, Ribavirin
- Where
- Egypt
- Sponsor
- Rottapharm
Hepatitis B, Acute-On-Chronic Liver Failure
RL-1 Novel Human-derived Bio-artificial Liver Treatment in Patients of HBV Related ACLF
This study is to investigate the clinical efficacy and safety of RL-1 Novel Human-derived Bio-artificial Liver treatment in patients with Hepatitis b virus related acute-on-chronic liver failure.
- Trial name
- NCT04195282
- Testing
- Plasma exchange, RL-1 Novel Human-derived Bio-artificial Liver Treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Hepatitis C, HIV Infections
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
This trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected patients with hepatitis C virus (HCV) genotype 1 or…
- Trial name
- NCT00470210
- Testing
- Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week, Ribavirin (Copegus®) 1600 mg/day, Epoetin β (450 UI/kg/week)
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Germans Trias i Pujol Hospital
Hepatitis B, Liver Cirrhosis
Application of HBV Rapid Tests as a Tool for Wide-Use Screening
With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year, hepatitis B is currently a frequent and potentially severe disease in France, despite efforts towards prevention and effective care.
- Conditions
- Hepatitis B, Liver Cirrhosis, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-B (NCT01767597)
- Testing
- ELISA testing, Rapid testing
- Where
- 5 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Chronic Hepatitis B
Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
The purpose of this study is to determine the optimal antiviral treatment for lamivudine resistant hepatitis B patients.
- Trial name
- NCT00798460
- Testing
- adefovir, clevudine, lamivudine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Inje University
Hepatitis A
Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
A phase IV, randomization, single center, controlled clinical trial to compare the safety, immunogenicity,three-year immune persistence of inactivated hepatitis A vaccine (HAV) with one- or two-dose regimen and live attenuated…
- Trial name
- NCT01865968
- Testing
- Inactivated HAV vaccine, Live attenuated HAV vaccine
- Where
- China
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
RNA Virus Infections, Flaviviridae Infections
Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C
The purpose of this study is to evaluate the effectiveness of the supplementation of vitamins D and B12 in combination with Pegylated Interferon-Alfa and Ribavirin in the treatment of genotype 1 chronic hepatitis C, who do not…
- Conditions
- RNA Virus Infections, Flaviviridae Infections, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT02120274
- Testing
- Vitamin D, Vitamin B 12
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Federal University of São Paulo
Chronic Hepatitis C, Cirrhosis
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed…
- Trial name
- NCT00048724
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 631 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025. The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.
- Trial name
- HOSPI-VHC (NCT04405024)
- Testing
- Hepatitis C testing
- Where
- 4 sites in France
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Hepatitis B Virus, HIV
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.
- Conditions
- Hepatitis B Virus, HIV, Antiretroviral Therapy, Africa
- Trial name
- NCT02060162
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 897 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis B Infection
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
- Trial name
- NCT03519113
- Testing
- GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Green Cross Corporation
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.